Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 8/20 | 0.46 |
| ▸ | KDM5C | P41229 | 6/20 | 0.46 |
| ▸ | KDM4A | O75164 | 5/20 | 0.46 |
| ▸ | KDM6B | O15054 | 3/20 | 0.46 |
| ▸ | KDM5A | P29375 | 3/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.43 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TET3 | O43151 | 1/20 | 0.41 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30097021 | 1.00 | ACACB (0.46) | ACACBACACAKDM5BKDM5CKDM4A | |
| SCHEMBL27426145 | 0.89 | ACACB (0.43) | ACACBACACAKDM5BKDM5CKDM4A | |
| SCHEMBL31133034 | 0.88 | ATR (0.47) | ACACBACACAKDM5BKDM5CKDM4A | |
| SCHEMBL10285171 | 0.88 | KDM5A (0.46) | ACACBACACAKDM5BKDM5CKDM4A | |
| SCHEMBL12682404 | 0.88 | ATR (0.47) | ACACBACACAKDM5BKDM5CKDM4A | |
| SCHEMBL7229830 | 0.86 | HDAC1 (0.47) | ACACBACACAKDM4ANAMPTMAPT | |
| SCHEMBL23706062 | 0.85 | ACACB (0.48) | ACACBACACAKDM5BKDM5CKDM4A | |
| SCHEMBL27640625 | 0.85 | CYP17A1 (0.46) | ACACBACACAKDM4ANAMPTL3MBTL1 | |
| SCHEMBL509487 | 0.85 | KDM5B (0.53) | ACACBACACAKDM5BKDM5CKDM5A | |
| SCHEMBL16020311 | 0.83 | KDM4A (0.44) | ACACBACACAKDM4ANAMPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-118812631-A | Fibroblast activator protein ligand for targeted delivery applications | 菲洛谢姆股份公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115335370-B | Fibroblast activator protein ligand for targeted delivery applications | 菲洛谢姆股份公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1763526-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Altana Pharma AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | MMP1, PIK3CA, AKT2 | ACACB 682/4885ACACA 862/4885KDM5B 3411/4885 |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | ACACB 1713/4885ACACA 2098/4885KDM5B 2399/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | ACACB 728/4885ACACA 1728/4885KDM5B 1944/4885 |
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | FAP, FIBP, FRS2 | ACACB 3398/4885ACACA 3721/4885KDM5B 2862/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | ACACB 3439/4885ACACA 3228/4885KDM5B 1873/4885 |
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR1 | ACACB 3168/4885ACACA 3450/4885KDM5B 3660/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ACACB 728/4885ACACA 1728/4885KDM5B 1944/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | ACACB 3304/4885ACACA 2581/4885KDM5B 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.